20 result(s) for 'RNAscope'
1 - 10 of 20 results for 'RNAscope'
Sort by
Show
This detection system is for in vitro diagnostic use.The BOND RNAscope® Brown Detection enables the user to perform chromogenic in situ hybridization (CISH) with Advanced Cell Diagnostics (ACD) proprietary RNA ISH probes. Performance claims for compatible probes have not been established. Probes used in conjunction with BOND RNAscope® Brown Detection should be validated by the user in accordance with local laws and regulations. The BOND RNAscope®...
Incorporation and Automation of RNAscope Technology into your COVID-19 Viral Pathogenesis Research. Research Use Only, Not for Clinical Diagnostic Procedure
For Research Use Only. Not For Diagnostic Use. Incorporation of the highly sensitive and specific RNAscope technology into your COVID-19 Viral Pathogenesis Research Jyoti Sheldon Applications Research Use Only, Not for Clinical Diagnostic Procedure
Agenda RNAscope technology overview COVID-19 Offerings COVID-19 Publications Research Use Only, Not for Clinical Diagnostic Procedure
RNAscope®In Situ Hybridization (ISH) Technology A hybridization-based signal amplification system with a unique probe design - Simultaneous signal amplification and background suppression Amplification Target-specific binding A specific and sensit...
Probes for the CE-IVD marked kit now available for clinical use.
Leica Biosystems, a global leader in pathology workflow solutions, previously partnered with Bio-Techne to create a fully automated, walk-away solution on the BOND-III IHC and ISH stainer, for use in automating RNA ISH. Now, Bio-Techne has registered probes for clinical utility within Europe for use with the RNAscope detection kit from Leica Biosystems. The CE-IVD marked RNAscope ISH Probe High Risk HPV is intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to aid in the identification of high-risk human papillomavirus (HPV).
RNAscope in situ hybridization is a highly sensitive and specific spatial biology technology that enables users to visualize and localize biomarker expr...
Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform
Leica Biosystems, in partnership with Bio-Techne Corporation, announces the automation of RNAscope™ COVID-19 probes’ on BOND RX*, its staining platform, for research use only. Researchers now have the capability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.
“We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Melissa Aquino, President, Leica Biosystems. “The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment ...
This white paper highlights the value of an integrated ISP-in situ hybridization (ISH) workflow for co-detection of protein and RNA targets on a single FFPE tissue section.
CAMBRIDGE, MASS., JANUARY 31, 2022.
Companion diagnostic supports patient identification and enrollment into clinical trials of Leap Therapeutics‘ DKK1 inhibitor, DKN-01
Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company, to develop a companion diagnostic to detect Dickkopfrelated protein 1 (DKK1). The assay will be used to support the clinical development of Leap Therapeutics’ anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials.
DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth. Overexpression of DKK1 is associated with poor survival in cancer patients. Leap Therapeutics is currently ...
It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases
Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects.
Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...
Following a PhD and postdoc in the field of developmental neurobiology, I joined the experimental histopathology team at the Crick in 2017. Within the science technology platform, I primarily lead on the development and application of advanced staining techniques including immunohistochemistry, immunofluorescence, multiplexed staining, and RNAscope.